Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.

Peethambaram PP, Hoskin TL, Day CN, Goetz MP, Habermann EB, Boughey JC.

NPJ Breast Cancer. 2017 Oct 19;3:41. doi: 10.1038/s41523-017-0044-4. eCollection 2017.

2.

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.

Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L.

Invest New Drugs. 2015 Apr;33(2):321-31. doi: 10.1007/s10637-014-0171-9. Epub 2014 Nov 8.

PMID:
25380635
3.

Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer.

AlHilli MM, Mariani A, Bakkum-Gamez JN, Dowdy SC, Weaver AL, Peethambaram PP, Keeney GL, Cliby WA, Podratz KC.

Gynecol Oncol. 2014 Jun;133(3):485-93. doi: 10.1016/j.ygyno.2014.03.567. Epub 2014 Mar 29.

4.

Safety of pegfilgrastim (neulasta) in patients with sickle cell trait/anemia.

Kasi PM, Patnaik MM, Peethambaram PP.

Case Rep Hematol. 2013;2013:146938. doi: 10.1155/2013/146938. Epub 2013 Dec 11.

5.

A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

Bible KC, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL, Boente M, Burton JK, Gomez Dahl LC, Tibodeau JD, Isham CR, Maguire JL, Shridhar V, Kukla AK, Voll KJ, Mauer MJ, Colevas AD, Wright J, Doyle LA, Erlichman C; Mayo Phase 2 Consortium (P2C); North Central Cancer Treatment Group (NCCTG).

Gynecol Oncol. 2012 Oct;127(1):55-62. Epub 2012 Jun 1.

6.

Cutaneous presentation of a distant metastasis of malignant phyllodes tumor.

Swapp RE, Shon W, Peethambaram PP, Moran SL, Reynolds C.

Int J Dermatol. 2012 Jan;51(1):72-4. doi: 10.1111/j.1365-4632.2011.04923.x. No abstract available.

PMID:
22182382
7.

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.

Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P.

Gynecol Oncol. 2012 Feb;124(2):210-5. doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1.

8.

Assessment of hepatocyte growth factor in ovarian cancer mortality.

Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, Vierkant RA, Larson MC, White KL, Keeney GL, Oberg TN, Cunningham JM, Beesley J, Johnatty SE, Chen X, Goodman KE, Armasu SM, Rider DN, Sicotte H, Schmidt MM, Elliott EA, Høgdall E, Kjær SK, Fasching PA, Ekici AB, Lambrechts D, Despierre E, Høgdall C, Lundvall L, Karlan BY, Gross J, Brown R, Chien J, Duggan DJ, Tsai YY, Phelan CM, Kelemen LE, Peethambaram PP, Schildkraut JM, Shridhar V, Sutphen R, Couch FJ, Sellers TA; Ovarian Cancer Association Consortium.

Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1638-48. doi: 10.1158/1055-9965.EPI-11-0455. Epub 2011 Jul 1.

9.

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P.

Gynecol Oncol. 2011 Jul;122(1):116-20. doi: 10.1016/j.ygyno.2011.03.030. Epub 2011 Apr 22.

10.
11.

Inherited determinants of ovarian cancer survival.

Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, Vierkant RA, Armasu SM, White KL, Keeney GL, Cliby WA, Rider DN, Kelemen LE, Jones MB, Peethambaram PP, Lancaster JM, Olson JE, Schildkraut JM, Cunningham JM, Hartmann LC.

Clin Cancer Res. 2010 Feb 1;16(3):995-1007. doi: 10.1158/1078-0432.CCR-09-2553. Epub 2010 Jan 26.

12.

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ.

Cancer Res. 2010 Feb 1;70(3):875-82. doi: 10.1158/0008-5472.CAN-09-2762. Epub 2010 Jan 26.

13.

A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.

Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW.

Clin Cancer Res. 2009 Sep 15;15(18):5937-44. doi: 10.1158/1078-0432.CCR-08-3282. Epub 2009 Sep 1.

14.

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

Litzow MR, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann SH.

Bone Marrow Transplant. 2010 Mar;45(3):490-7. doi: 10.1038/bmt.2009.181. Epub 2009 Aug 3.

15.

Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions.

McKean H, Looker S, Hartmann LC, Hayman SR, Kaur JS, McWilliams RR, Peethambaram PP, Stahl JF, Jatoi A.

J Nutr Educ Behav. 2008 May-Jun;40(3):144-8. doi: 10.1016/j.jneb.2007.08.009.

PMID:
18457782
16.

A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.

Dy GK, Mandrekar S, Peethambaram PP, Okuno SH, Croghan GC, Hanson LJ, Furth A, Adjei AA.

Cancer Chemother Pharmacol. 2005 Dec;56(6):623-8. Epub 2005 Jul 6.

PMID:
15999272
17.

Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.

Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J.

Cancer. 2004 Dec 1;101(11):2557-66.

18.

Pelvic primitive neuroectodermal tumor associated with a cluster of small round cell tumors: case report and review of current literature.

Gostout BS, Lindor NM, DiMarco CS, Peethambaram PP, Clayton AC.

Gynecol Oncol. 2003 Oct;91(1):247-53. Review.

PMID:
14529689
19.

Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy.

Peethambaram PP, Cliby WA, Lubiniecki G, Clayton AC, Roche PC, Iturria SJ, Hartmann LC, Hellström I, Strome SE.

Gynecol Oncol. 2003 Apr;89(1):99-104.

PMID:
12694661
20.

Second-line and subsequent therapy for ovarian carcinoma.

Peethambaram PP, Long HJ.

Curr Oncol Rep. 2002 Mar;4(2):159-64. Review.

PMID:
11822988
21.

Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.

Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL.

Breast Cancer Res Treat. 1999 Mar;54(2):117-22.

PMID:
10424402
22.

Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors.

Buckner JC, Peethambaram PP, Smithson WA, Groover RV, Schomberg PJ, Kimmel DW, Raffel C, O'Fallon JR, Neglia J, Shaw EG.

J Clin Oncol. 1999 Mar;17(3):933-40.

PMID:
10071287
23.

Management of menopausal symptoms in breast cancer patients.

Loprinzi CL, Peethambaram PP.

Ann Med. 1995 Dec;27(6):653-6. No abstract available.

PMID:
8652144

Supplemental Content

Loading ...
Support Center